Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
Philip A Philip, Michelle R Mahoney, Kyle D Holen, Donald W Northfelt, Henry C Pitot, Joel Picus, Patrick J Flynn, Charles Erlichman, Philip A Philip, Michelle R Mahoney, Kyle D Holen, Donald W Northfelt, Henry C Pitot, Joel Picus, Patrick J Flynn, Charles Erlichman
Abstract
Background: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC).
Methods: Patients with histologically proven HCC and not amenable to curative or liver directed therapy were included in this 2-stage phase 2 trial. Eligibility included an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 and Child's Pugh score of A or B, and 1 prior systemic therapy. Patients received erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days. Objective tumor response was the primary end point.
Results: Twenty-seven patients with advanced HCC (median age, 60 years) were enrolled in this multi-institutional study. The proportion of patients with Child's A classification was 74%. One patient had a confirmed partial response and 11 (48%) achieved stable disease. Median time to disease progression was 3.0 months (95% confidence interval [CI], 1.8-7.1). Median survival time was 9.5 months (95% CI, 7.1-17.1). Grade 3 toxicities included rash, hypertension, fatigue, and diarrhea.
Conclusions: In this trial, erlotinib combined with bevacizumab had minimal activity in patients with advanced HCC based on objective response and progression-free survival. The role of targeting EGFR and VEGF in HCC needs further evaluation in molecularly selected patients.
Trial registration: ClinicalTrials.gov NCT00365391.
Conflict of interest statement
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
Copyright © 2011 American Cancer Society.
Figures
Source: PubMed